GrayMatters Health FDA cleared Prism for PTSD — first self-neuromodulation device for PTSD using EEG-fMRI amygdala biomarker
Summary
GrayMatters Health received FDA 510(k) clearance for Prism for PTSD — the first FDA-cleared self-neuromodulation therapy for post-traumatic stress disorder. Prism uses a proprietary EEG-fMRI Pattern (EFP) biomarker derived from the patient's own brain imaging, creating a personalized fingerprint of amygdala emotional regulation activity. During 30-minute clinic sessions, patients interact with audio-visual software while their real-time EEG is compared to their personal EFP biomarker, training them to consciously lower amygdala hyperactivity through mental strategy exploration. The technology was licensed from Professor Talma Hendler at Tel Aviv University. The European Innovation Council (EIC) made a direct equity investment; Otsuka Medical Devices (Japan) is an investor and development partner. GrayMatters is expanding to depression (reward system biomarker), ADHD, anxiety, and borderline personality disorder.
Why it matters
Prism is the first FDA-cleared device that trains patients to self-regulate their amygdala activity — the neurological core of PTSD. Unlike TMS or tDCS which passively stimulate the brain, Prism makes the patient an active participant in changing their own brain activity through learned mental strategies. This "agency" model — patients developing and applying strategies they own — has better adherence and durability than passive stimulation, and the EEG-fMRI biomarker makes each patient's treatment individually calibrated rather than protocol-standardized.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial